Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 5:38 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Parkinsons Disease (PD) Clear all
Active, not recruiting No phase listed Observational

Quantification of Phosphorylated Alpha-synuclein in Cutaneous Biopsies as a Prospective Biomarker in Parkinson's Disease

NCT06621602
View directory record Official record
Conditions
REM Behavior Disorder, Parkinson Disease
Interventions
Not listed
Lead sponsor
CND Life Sciences
Other
Eligibility
50 Years to 85 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
18
States / cities
Scottsdale, Arizona • Aliso Viejo, California • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Jun 10, 2026, 5:38 AM EDT
Recruiting No phase listed Observational

Modifiable Variables in Parkinsonism (MVP)

NCT02194816
View directory record Official record
Conditions
Parkinson's Disease, Parkinsonism, MSA - Multiple System Atrophy, Progressive Supranuclear Palsy, Shy-Drager Syndrome, Corticobasal Degeneration, Dementia With Lewy Bodies, Pick Disease, Olivopontocerebellar Atrophies
Interventions
Not listed
Lead sponsor
Bastyr University
Other
Eligibility
19 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2030
U.S. locations
1
States / cities
Kenmore, Washington
Source: ClinicalTrials.gov public record
Updated Mar 24, 2022 · Synced Jun 10, 2026, 5:38 AM EDT
Recruiting Phase 2 Interventional

A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD)

NCT06285643
View directory record Official record
Conditions
Parkinson Disease
Interventions
AAV2-GDNF gene therapy, control surgery
Drug · Procedure
Lead sponsor
AskBio Inc
Industry
Eligibility
45 Years to 75 Years
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
27
States / cities
Irvine, California • Loma Linda, California • San Francisco, California + 19 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2025 · Synced Jun 10, 2026, 5:38 AM EDT
Completed Phase 3 Interventional Results available

Long-term Safety Study of Open-label Pramipexole Extended Release (ER) in Patients With Early Parkinson´s Disease (PD).

NCT00601523
View directory record Official record
Conditions
Parkinson Disease
Interventions
Placebo, Pramipexole
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
30 Years and older
Enrollment
511 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
10
States / cities
Sun City, Arizona • Tempe, Arizona • La Jolla, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2014 · Synced Jun 10, 2026, 5:38 AM EDT
Completed Phase 4 Interventional Results available

Solifenacin Succinate (VESIcare) for the Treatment of Overactive Bladder in Parkinson's Disease

NCT01018264
View directory record Official record
Conditions
Overactive Bladder in Parkinson's Disease
Interventions
solifenacin succinate (VESIcare), placebo
Drug
Lead sponsor
University of South Florida
Other
Eligibility
40 Years to 80 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
3
States / cities
Miami, Florida • Tampa, Florida • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 8, 2021 · Synced Jun 10, 2026, 5:38 AM EDT
Active, not recruiting Phase 2 Interventional

A Phase 2a Multicenter Clinical Trial of TB006 in Participants With Parkinson's Disease

NCT06773962
View directory record Official record
Conditions
Parkinson's Disease (PD)
Interventions
TB006, Placebo
Drug
Lead sponsor
TrueBinding, Inc.
Industry
Eligibility
50 Years to 80 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
14
States / cities
Aliso Viejo, California • Palo Alto, California • Englewood, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Jun 10, 2026, 5:38 AM EDT
Active, not recruiting Phase 2 Interventional

Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD)

NCT06602193
View directory record Official record
Conditions
Parkinson Disease
Interventions
BIIB122 225 mg, BIIB122-Matching Placebo
Drug · Other
Lead sponsor
Denali Therapeutics Inc.
Industry
Eligibility
30 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
7
States / cities
Los Angeles, California • San Francisco, California • Boca Raton, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Jun 10, 2026, 5:38 AM EDT
Completed Phase 1 Interventional

VY-AADC02 for Parkinson's Disease With Motor Fluctuations (RESTORE-1)

NCT03562494
View directory record Official record
Conditions
Parkinson's Disease
Interventions
VY-AADC02, Sham (Placebo) Surgery
Biological · Other
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
40 Years to 75 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
11
States / cities
Irvine, California • Sacramento, California • San Francisco, California + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2024 · Synced Jun 10, 2026, 5:38 AM EDT
Completed Phase 2 Interventional

Phase 2A Study of GM 608 in Mild to Moderate Parkinson Disease

NCT01850381
View directory record Official record
Conditions
Parkinson's Disease
Interventions
GM608, Placebo Comparator
Drug
Lead sponsor
Genervon Biopharmaceuticals, LLC
Industry
Eligibility
30 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 7, 2019 · Synced Jun 10, 2026, 5:38 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Phase 1/2a Clinical Trial of PR001 (LY3884961) in Patients With Parkinson's Disease With at Least One GBA1 Mutation (PROPEL)

NCT04127578
View directory record Official record
Conditions
Parkinson Disease
Interventions
LY3884961, Methylprednisolone, Sirolimus
Biological · Drug
Lead sponsor
Prevail Therapeutics
Industry
Eligibility
35 Years to 80 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
11
States / cities
Scottsdale, Arizona • Murrieta, California • Englewood, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Jun 10, 2026, 5:38 AM EDT
Completed No phase listed Observational Results available

Airway Protective Mechanisms in PD (R01)

NCT03321019
View directory record Official record
Conditions
Parkinson Disease
Interventions
Capsaicin, Resistive respiratory loads, Event-related evoked potential using electroencephalography (EEG)., Fluoroscopic swallow evaluation
Drug · Device · Other + 1 more
Lead sponsor
University of Florida
Other
Eligibility
45 Years to 85 Years
Enrollment
119 participants
Timeline
2017 – 2023
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 9, 2024 · Synced Jun 10, 2026, 5:38 AM EDT
Completed No phase listed Observational

Defining Phenotypes of Movement Disorders :Parkinson's Plus Disorders (PD), Essential Tremor (ET), Cortical Basal Degeneration (CBD), Multiple Systems Atrophy (MSA), Magnetoencephalography.

NCT02132052
View directory record Official record
Conditions
Essential Tremor, Multiple System Atrophy, Corticobasal Degeneration, Supranuclear Palsy, Progressive, Parkinson Disease
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
40 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 24, 2021 · Synced Jun 10, 2026, 5:38 AM EDT
Recruiting Not applicable Interventional

Daily Amino Acid Supplementation for People With Parkinson's Disease

NCT07115563
View directory record Official record
Conditions
Parkinson Disease (PD)
Interventions
Targeted Amino Acid Supplement, Control (placebo)
Dietary Supplement
Lead sponsor
Cristina Colon-Semenza
Other
Eligibility
60 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Storrs, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Jun 10, 2026, 5:38 AM EDT
Terminated Phase 3 Interventional Results available

Phase 3 Open-Label Extension Study of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure

NCT04095793
View directory record Official record
Conditions
Symptomatic Neurogenic Orthostatic Hypotension
Interventions
ampreloxetine
Drug
Lead sponsor
Theravance Biopharma
Industry
Eligibility
30 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
13
States / cities
Colorado Springs, Colorado • Boca Raton, Florida • Port Charlotte, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2022 · Synced Jun 10, 2026, 5:38 AM EDT
Recruiting Not applicable Interventional

Transcranial Direct Current Stimulation for Motor Function and Fatigue in PD

NCT06883266
View directory record Official record
Conditions
Parkinsons Disease (PD)
Interventions
transcranial direct current stimulation (tDCS), Sham (No Treatment)
Device
Lead sponsor
Sanford Health
Other
Eligibility
Not listed
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Jun 10, 2026, 5:38 AM EDT
Completed Phase 2 Interventional Results available

A Comparison of an Implanted Neuroprosthesis With Sensory Training for Improving Airway Protection in Chronic Dysphagia

NCT00376506
View directory record Official record
Conditions
Chronic Dysphagia, Multiple Sclerosis, Parkinson Disease
Interventions
Neurostimulation device for dysphagia, External vibrotactile device
Device
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 90 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 25, 2012 · Synced Jun 10, 2026, 5:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effect of Rifampin on the Metabolism of Istradefylline in Healthy Volunteers.

NCT02174250
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Istradefylline 40 mg, Rifampin 300mg BID + istradefylline 40mg Day 8 only
Drug
Lead sponsor
Kyowa Kirin Co., Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Jun 10, 2026, 5:38 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Meals Study for Amyotrophic Lateral Sclerosis and Parkinson's Disease

NCT07625605
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS), Parkinson's Disease (PD)
Interventions
The MIND diet
Behavioral
Lead sponsor
The University of Tennessee, Knoxville
Other
Eligibility
30 Years and older
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
3
States / cities
Elizabethton, Tennessee • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Jun 10, 2026, 5:38 AM EDT
Completed Phase 2 Interventional Results available

Transcranial Direct Current Stimulation to Treat Symptoms of Parkinson's Disease

NCT00082342
View directory record Official record
Conditions
Parkinson Disease
Interventions
Phoressor II (IOMED)
Device
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
40 Years to 80 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 26, 2012 · Synced Jun 10, 2026, 5:38 AM EDT
Completed Phase 3 Interventional Results available

Open-Label Safety Study of ADS-5102 in PD Patients With LID

NCT02202551
View directory record Official record
Conditions
Dyskinesia, Levodopa Induced Dyskinesia (LID), Parkinson's Disease (PD)
Interventions
ADS-5102
Drug
Lead sponsor
Adamas Pharmaceuticals, Inc.
Industry
Eligibility
30 Years to 85 Years
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
54
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2020 · Synced Jun 10, 2026, 5:38 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Respiratory Load Magnitude Estimation in PD

NCT02202057
View directory record Official record
Conditions
Parkinson's Disease, Aging
Interventions
Respiratory resistive load on inhalation, Fluoroscopic swallowing evaluation
Other
Lead sponsor
University of Florida
Other
Eligibility
45 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 18, 2016 · Synced Jun 10, 2026, 5:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy Subjects

NCT02103894
View directory record Official record
Conditions
Alzheimer's Disease (AD), Parkinson's Disease (PD), Chronic Traumatic Encephalopathy (CTE), Progressive Supranuclear Palsy (PSP), Frontal Temporal Dementia (FTD), Pick's Disease, Tauopathies
Interventions
[18F]T807 ([18F]MNI-777)
Drug
Lead sponsor
Molecular NeuroImaging
Other
Eligibility
18 Years to 85 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 15, 2016 · Synced Jun 10, 2026, 5:38 AM EDT
Completed Not applicable Interventional Results available

Combining VNS With PT Interventions for Individuals With PD

NCT05871151
View directory record Official record
Conditions
Parkinson Disease
Interventions
taVNS, Exercise
Device · Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
35 Years to 80 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
2
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Jun 10, 2026, 5:38 AM EDT
Recruiting Not applicable Interventional

Use of CereGate Therapy for Freezing of Gait in PD

NCT05292794
View directory record Official record
Conditions
Parkinson Disease, Freezing of Gait, Deep Brain Stimulation
Interventions
CereGate Software; BSN cDBS Programmer; BSN Burst Programmer
Device
Lead sponsor
CereGate Inc.
Industry
Eligibility
21 Years to 80 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
7
States / cities
Redwood City, California • Aurora, Colorado • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Jun 10, 2026, 5:38 AM EDT